CA
NZ
UK
AU
IND
US
• Skyrizi Eclipses Humira: Skyrizi hit $4.5 billion in Q1 2026 revenue, surpassing Humira's peak and easing the post-Humira transition.
• S&P 500's Best Quarter in Six Years Sets the Stage: The S&P 500's strongest quarterly performance since 2020 created an exceptionally favorable backdrop for financial infrastructure and data stocks.
• Twin Target Hikes: BofA Securities lifted its target to $36 from $25 (Neutral), while Canaccord Genuity raised its Buy-rated target to $40 from $32.
• FDA Flags Seven Peptides: FDA scientists raised safety questions about seven popular peptides, an overnight headwind for compounding-reliant telehealth.
• Medicare Obesity Coverage: A temporary Medicare move to cover obesity drugs like Wegovy broadens Novo Nordisk's addressable U.S. market.
• Manufacturers Set the Pace: Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) anchor the obesity-drug market, driving demand and pricing across the chain.
• ARK Adds Shares: ARK Invest added over 260,000 shares, signaling continued institutional interest in Recursion's AI drug discovery platform.
• Trading Near 52-Week Lows: Boston Scientific (NYSE: BSX) hovers near yearly lows even as the healthcare sector trades near 52-week highs.
• Both Stocks Beat the Market Simultaneously: Moody's and S&P Global both outperformed the S&P 500 in the same session despite pursuing entirely different strategic initiatives.
• First Stablecoin From a US National Bank: SoFi Technologies launched SoFiUSD, becoming the first US national bank to issue a stablecoin with full federal regulatory standing.
Please wait processing your request...